Last reviewed · How we verify
Quetiapine and Topiramate
This combination uses quetiapine's dopamine and serotonin antagonism for antipsychotic/mood effects alongside topiramate's sodium channel blockade and carbonic anhydrase inhibition for mood stabilization and anticonvulsant activity.
This combination uses quetiapine's dopamine and serotonin antagonism for antipsychotic/mood effects alongside topiramate's sodium channel blockade and carbonic anhydrase inhibition for mood stabilization and anticonvulsant activity. Used for Bipolar disorder (off-label combination), Treatment-resistant depression (off-label combination), Schizophrenia with mood instability (off-label combination).
At a glance
| Generic name | Quetiapine and Topiramate |
|---|---|
| Also known as | Topiramate |
| Sponsor | University of Cincinnati |
| Drug class | Atypical antipsychotic + anticonvulsant mood stabilizer combination |
| Target | D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Quetiapine is an atypical antipsychotic that blocks D2 dopamine and 5-HT2A serotonin receptors, used for psychosis and bipolar disorder. Topiramate is an anticonvulsant that blocks voltage-gated sodium channels and inhibits carbonic anhydrase, providing mood-stabilizing and neuroprotective effects. The combination leverages both agents' psychiatric benefits, though this is an off-label polypharmacy approach rather than a single fixed-dose entity.
Approved indications
- Bipolar disorder (off-label combination)
- Treatment-resistant depression (off-label combination)
- Schizophrenia with mood instability (off-label combination)
Common side effects
- Sedation/somnolence
- Weight gain
- Cognitive impairment
- Dizziness
- Dry mouth
- Paresthesias (topiramate)
Key clinical trials
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania (PHASE4)
- Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults (PHASE4)
- Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism (PHASE4)
- Juvenile Bipolar Disorder Outpatient Program (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quetiapine and Topiramate CI brief — competitive landscape report
- Quetiapine and Topiramate updates RSS · CI watch RSS
- University of Cincinnati portfolio CI